Research Grade Bemarituzumab

Catalog No.	HB863016
Host species	Humanized
Species reactivity	Human
Form	Liquid
Storage buffer	0.01M PBS, pH 7.4.
Purity	>95% purity as determined by SDS-PAGE.
Clonality	Monoclonal
Isotype	IgG1-kappa
Applications	ELISA, Bioactivity: FACS, Functional assay, Research in vivo
Target	K-sam, KSAM, CD332, Keratinocyte growth factor receptor, Fibroblast growth factor receptor 2, FGFR-2, FGFR2, KGFR, BEK
Purification	Protein A/G purified from cell culture supernatant.
Endotoxin level	Please contact the lab for this information.
Expression system	Mammalian Cells
Accession	P21802
Stability and Storage	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C.
Alternative name	FPA144, FPA-144, FPA114-A, 1952272-74-0
Note	For research use only. Not suitable for clinical or therapeutic use.

Bemarituzumab (bema), a first-in-class humanized IgG1 monoclonal antibody, selectively binds to the 2b isoform of the fibroblast growth factor receptor (FGFR2b). Bemarituzumab (FPA144) is a first-in-class humanized immunoglobulin G1 monoclonal antibody specific to the splice-variant FGFR2b that inhibits binding of the ligands FGF7, FGF10, and FGF22. Specifically, bemarituzumab does not inhibit binding of FGF23, the ligand responsible for phosphate and vitamin D metabolism, thereby potentially avoiding the risk of hyperphosphatemia associated with pan-FGFR tyrosine kinase inhibitors. Bemarituzumab is also glycoengineered for increased affinity for the human Fc gamma RIII receptor expressed on natural killer cells, enabling enhanced antibody-dependent cell-mediated cytotoxicity.

Bioactivity	SEC-HPLC detection for Research Grade Bemarituzumab.
SDS-PAGE	SDS-PAGE for Research Grade Bemarituzumab.